ARQ-151 not checked
Arcutis Biotherapeutics, Inc. · Roflumilast Cream 0.15% · Roflumilast Foam 0.3%
FollowEvery change as it happens, and a Monday email
Trials
2 active
24 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Roflumilast cream 0.3% administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants may continue treatment with roflumilast cream 0.3% during the 48-week open-label extension.”In the company’s words, NCT07916480 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis (2 trials), ITCH, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
- Main trialPhase 4
- “This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.”In the company’s words, NCT07560618 on ClinicalTrials.gov
- Other names
- Roflumilast Cream 0.15% · Topical roflumilast · Roflumilast Foam 0.3% · Roflumilast Cream · Roflumilast Cream 0.05% · Roflumilast 0.3% cream · ARQ-154 · Roflumilast Foam · Roflumilast · ARQ-154 0.3% · Roflumilast Cream 0.3%
Other drugs for Atopic Dermatitis
Coming up2
- Aug 2027Phase 4 trial completes · ClinicalTrials.gov
- 27 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials24
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Aug 2027 | Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. | |
| Phase 3Recruiting | 27 Apr 2028 | Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis | |
| Phase 3Completed | 16 Nov 2020 | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | |
| Phase 3Completed | 23 Nov 2020 | Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | |
| Phase 3Completed | 6 Apr 2022 | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) | |
| Phase 3Completed | 3 Jun 2022 | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) | |
| Phase 3Completed | 30 Aug 2022 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | |
| Phase 3Completed | 29 Sep 2022 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) | |
| Phase 3Completed | 1 Jun 2023 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) | |
| Phase 3Completed | 22 Jan 2024 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | |
| Phase 3Completed | 28 May 2024 | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | |
| Phase 2Completed | 29 May 2019 | The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis | |
| Phase 2Completed | 4 Nov 2019 | Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis | |
| Phase 2Completed | 18 Aug 2020 | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | |
| Phase 2Completed | 23 Sep 2020 | Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis | |
| Phase 2Completed | 12 Jan 2022 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) | |
| Phase 2Completed | 11 May 2022 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) | |
| Phase 2Completed | 19 Nov 2022 | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | |
| Phase 2Completed | 4 Dec 2025 | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis | |
| Phase 1/2Completed | 2 May 2018 | Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis | |
| Phase 1Completed | 25 Mar 2021 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis | |
| Phase 1Completed | 2 May 2023 | Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema | |
| Phase 1Completed | 30 Apr 2026 | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis | |
| Phase 2Ended | not given | Treatment of Chronic Hand Eczema with Oral Roflumilast (HERO) – a randomized controlled trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026